Has Jose Alvarez, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,618 in general payments to Jose Alvarez, MD across 29 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jose Alvarez, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jose Alvarez, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jose Alvarez, MD

General Practice · Miami, FLNPI 1205873817

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $6,600 of the $7,618 with a category attached, or 86.6%. AbbVie accounts for 90.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $5,048 and has fallen 99.4% since, to $29 in 2025. Among general practice clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,618in general payments, 2019–2025

Across 29 payments — averaging $262.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$7K
Sunovion Pharmaceuticals Inc.$159
Otsuka America Pharmaceutical, Inc.$143
Boston Scientific$125
Biosense Webster, Inc.$104
Siemens Medical Solutions USA, Inc.$66
plus $134 from 4 others

$306,983in research payments, 2019–2025

Across 64 payments — averaging $4796.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Teva Pharmaceuticals USA, Inc.$166K
Sanofi US Services Inc.$43K
AstraZeneca$43K
Lexicon Pharmaceuticals, Inc.$20K
Novo Nordisk AS$18K
Chiesi USA, Inc.$10K
plus $7K from 1 others

What the payments were for

Speaking & faculty fees$6,60087%
Food & beverage$1,01813%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	8	$6,886
Sunovion Pharmaceuticals Inc.	7	$159
Otsuka America Pharmaceutical, Inc.	2	$143
Boston Scientific	2	$125
Biosense Webster, Inc.	2	$104
Siemens Medical Solutions USA, Inc.	3	$66
Impulse Dynamics (USA) Inc.	1	$51
Abbott	2	$31
Lundbeck LLC	1	$29
Exact Sciences	1	$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,618 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida →

Medicare billing

Part B allowed, 2024

$292,814

Medicare patients

Services billed

227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	88	$56,162
OzempicSemaglutide	25	$24,361
XareltoRivaroxaban	16	$20,065
JanuviaSitagliptin Phosphate	30	$17,645
MounjaroTirzepatide	14	$16,175
FarxigaDapagliflozin Propanediol	20	$11,822
Albuterol Sulfate HfaAlbuterol Sulfate	327	$9,424
TradjentaLinagliptin	18	$9,063
SymbicortBudesonide/Formoterol Fumarate	36	$8,183
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	60	$6,344
Rosuvastatin Calcium	615	$3,554
Insulin Aspart FlexpenInsulin Aspart	11	$2,628
Levothyroxine Sodium	378	$2,454
Dabigatran EtexilateDabigatran Etexilate Mesylate	14	$2,098
Oxybutynin Chloride ErOxybutynin Chloride	115	$1,941

Paid to pharmacies, not to this prescriber.

Other general practice in Miami

Idalia AcostaMiami$99K
Eddie GomezMiami$59K
Aladino ValienteMiami$24K
Viviana WaichMiami$20K
Libia RiosMiami$15K
Jose CardonaMiami$15K
Rosa HuguetMiami$15K
Robert VogelPalm Beach Gardens$1M
Bruce OuelletteWest Palm Beach$724K
Caley CasteleinMiami Beach$586K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →